Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:

Free Newsletter

  Email address:

Tasly to Start Phase III Trial of TCM Angina Treatment in US

publication date: Aug 9, 2010
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.
Tianjin Tasly Pharmaceutical said its patented TCM treatment for angina, Compound Danshen Dripping Pills, posted positive results in a Phase II trial conducted in the US. The FDA has also given its go-ahead to move the drug into Phase III trials, according to Tasly. Assuming a positive outcome for the trial, the company hopes to launch the drug in the US as early as 2013. Tasly said Danshen is the first TCM drug approved by the FDA for Phase III trials. More details....

Stock Symbol: (SHEX: 600535)

Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...



Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China

>>More events...
Our Partners
Annual Sponsors
Official Partners
Supporting Partners
Media Partners